Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 15 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03546361Phase 1 Report a problem
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownNCT03544723Phase 2 Report a problem
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic MelanomaCompletedNCT03538314Phase 1 Report a problem
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)Active, not recruitingNCT03534635Phase 2 Report a problem
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3 Report a problem
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid TumorsCompletedNCT03511391Phase 2 Report a problem
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid TumorsTerminatedNCT03511222Phase 1 Report a problem
A Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerActive, not recruitingNCT03505320Phase 2 Report a problem
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabCompletedNCT03486301Phase 1 Report a problem
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingNCT03485209Phase 2 Report a problem
Study of NEO-201 in Solid Tumors Expansion CohortsActive, not recruitingNCT03476681Phase 1/2 Report a problem
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLTerminatedNCT03471351Phase 1 Report a problem
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedNCT03454451Phase 1 Report a problem
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTCompletedNCT03435952Phase 1 Report a problem
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerWithdrawnNCT03432676Phase 2 Report a problem
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLCTerminatedNCT03417882Phase 2 Report a problem
Study of AGEN1884 With Pembrolizumab in 1L NSCLCTerminatedNCT03411473Phase 2 Report a problem
Apatinib With Pembrolizumab in Previously Treated Advanced MalignanciesTerminatedNCT03407976Phase 1 Report a problem
ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT03402880Phase 2 Report a problem
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung CancerStatus unknownNCT03396497Phase 1 Report a problem
Combination of Immunotherapy and Hyperthermia in Advanced Malignant MesotheliomaTerminatedNCT03393858Phase 1/2 Report a problem
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by SurgerySuspendedNCT03384836Phase 1/2 Report a problem
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung CancerCompletedNCT03380871Phase 1 Report a problem
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCStatus unknownNCT03371992Early Phase 1 Report a problem
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerActive, not recruitingNCT03362060Phase 1 Report a problem
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaActive, not recruitingNCT03361852Phase 1 Report a problem
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLCCompletedNCT03360630Phase 1/2 Report a problem
TNF in Melanoma Patients Treated With ImmunotherapyCompletedNCT03348891Not applicable Report a problem
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1 Report a problem
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1 Report a problem
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03325465Phase 2 Report a problem
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT03319940Phase 1 Report a problem
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive, not recruitingNCT03313778Phase 1 Report a problem
T-Cell PET Imaging With [18F]F-AraG in Lung CancerWithdrawnNCT03311672Phase 2 Report a problem
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced MelanomaActive, not recruitingNCT03311308Phase 1 Report a problem
A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial CarcinomaWithdrawnNCT03310567Phase 2 Report a problem
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/2 Report a problem
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1 Report a problem
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 TherapyCompletedNCT03278665Phase 1/2 Report a problem
A Study of ADXS-NEO Expressing Personalized Tumor AntigensTerminatedNCT03265080Phase 1 Report a problem
Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabStatus unknownNCT03263039Phase 2 Report a problem
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT03260322Phase 1 Report a problem
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersTerminatedNCT03254732Phase 1 Report a problem
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal CancerCompletedNCT03251612Phase 2 Report a problem
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SDTerminatedNCT03246685Phase 2 Report a problem
Anti-platelet + Pembro for H&N TumorsCompletedNCT03245489Phase 1 Report a problem
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLActive, not recruitingNCT03240211Phase 1 Report a problem
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 TherapyWithdrawnNCT03238638Phase 2 Report a problem
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2 Report a problem
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally AdvancedActive, not recruitingNCT03225664Phase 1/2 Report a problem
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.CompletedNCT03224871Early Phase 1 Report a problem
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingNCT03220477Phase 1 Report a problem
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple MyelomaWithdrawnNCT03191981Phase 1/2 Report a problem
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid TumorsCompletedNCT03190811Phase 1/2 Report a problem
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal CancerWithdrawnNCT03182894Phase 1/2 Report a problem
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive, not recruitingNCT03179930Phase 2 Report a problem
Special Combination of OBP-301 and PembrolizumabCompletedNCT03172819Phase 1 Report a problem
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic CancerCompletedNCT03168139Phase 1/2 Report a problem
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung CancerWithdrawnNCT03166254Phase 1 Report a problem
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruitingNCT03161431Phase 1 Report a problem
Study of AMV564 in Patients With AMLCompletedNCT03144245Phase 1 Report a problem
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDXCompletedNCT03134456Phase 4 Report a problem
Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab TreatmentStatus unknownNCT03132675Phase 2 Report a problem
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossCompletedNCT03131908Phase 1/2 Report a problem
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedNCT03129061Phase 1 Report a problem
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell CancerWithdrawnNCT03111901Phase 1/2 Report a problem
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedNCT03084640Phase 1 Report a problem
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingNCT03030378Phase 1 Report a problem
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2 Report a problem
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1 Report a problem
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line TherapyTerminatedNCT03013946Phase 3 Report a problem
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)CompletedNCT03013218Phase 1 Report a problem
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1 Report a problem
Combination Study of Guadecitabine/ASTX727 and PembrolizumabActive, not recruitingNCT02998567Phase 1 Report a problem
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV MelanomaStatus unknownNCT02990416Phase 1/2 Report a problem
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2 Report a problem
A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1 Report a problem
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1 Report a problem
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial TractTerminatedNCT02925533Phase 1 Report a problem
A Study of RGX-104 in Patients With Advanced Lung & Endometrial CancerCompletedNCT02922764Phase 1 Report a problem
IL2 Imaging in Metastatic MelanomaTerminatedNCT02922283Not applicable Report a problem
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCompletedNCT02909452Phase 1 Report a problem
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1 Report a problem
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 MonotherapyWithdrawnNCT02880345Phase 1 Report a problem
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedNCT02879760Phase 1/2 Report a problem
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2 Report a problem
Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1 Report a problem
Special Combination of BBI608 and PembrolizumabTerminatedNCT02851004Phase 1/2 Report a problem
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid TumorsCompletedNCT02843204Phase 1/2 Report a problem
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerTerminatedNCT02842125Phase 1/2 Report a problem
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerCompletedNCT02840994Phase 1 Report a problem
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid TumorsCompletedNCT02828098Phase 1 Report a problem
Pembrolizumab + CVA21 in Advanced NSCLCStatus unknownNCT02824965Phase 1 Report a problem
X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedNCT02823405Phase 1 Report a problem
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1 Report a problem
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedNCT02798406Phase 2 Report a problem
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsCompletedNCT02794571Phase 1 Report a problem
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingNCT02779751Phase 1 Report a problem
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2 Report a problem
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsTerminatedNCT02757391Phase 1 Report a problem

← Pembrolizumab